Connect with us

Featured

Medical Marijuana In The Healthcare Space

Daniel Chase

Published

on

stock_price_marijuana

If there’s one thing that is absolutely certain in life, it is that no matter who you are or where you come from, health is the core factor that connects every living person on the planet. Everyone wants to live enjoyable, healthy lives but things happen and we get injured, or fall ill. In developed nations like the United States and Canada, access to healthcare is just part of one’s daily regimen. We expect health care professionals to take care of us when we’re not feeling well, but millions of people around the world live with little to no access to primary care

The most recent global report from the United Nations states that by 2030, the global population will reach 8.6 billion. Based on these projections, it’s fair to predict that access to global resources will begin to dwindle, including housing, food, and most crucially healthcare. Luckily, there are companies in the healthcare sector that are working to help patients receive the care they need through innovative medical technologies and nuanced approaches to care options. 

Premier Health Group Inc (OTC: PHGRF) / (CSE:PHGI) is one such company that is strategically poised to take advantage of business opportunities in the global health care industry. Over the course of the last few years, Premier Health has garnered nearly 3,000,000 (three million patients), an ecosystem of 290 clinics, and 4,600 licensed practitioners. Suffice to say that the Company has been received well by both members of the medical community as well as patients in search of qualitative care. 

Over the course of the last decade or so, we’ve seen a societal shift in how people view cannabis in terms of the stigmas historically associated with the plant, as well as humoring the potential benefits of medicinal cannabis. In the United States, usage of cannabis for medicinal purposes is legal in thirty-three states, and nearly every state has some form of codified legal cannabis usage.

We are seeing a tidal shift among the medical community regarding the cannabis sector and the potential benefits of incorporating medicinal cannabis and CBD into healthcare. Leaping ahead, Premier Health Group Inc (OTC:PHGRF) / (CSE:PHGI) has made it clear their plans to launch a Cannabis Clinic and incorporate cannabis into its treatment options. 

Premier Health Group Inc (OTC:PHGRF) / (CSE:PHGI) made headlines yesterday when the Company announced that it has initiated integration of CB2 Insights’ (CBII.CN) medical cannabis Clinical Decision Support tool. For those unfamiliar with CB2, the Company operates 28 medical cannabis evaluation centers staffed with physicians and healthcare practitioners and creates both access for patients who qualify for medical cannabis as well as a center of excellence to study and understand the clinical outcomes of cannabinoid therapy.

Per the details of Premier Health Group Inc (OTC:PHGRF) / (CSE:PHGI)’s agreement with CB2 Insights, the deal will give more than 4600 physicians and healthcare practitioners using Premier Health’s Juno EMR platform access to the industry’s only medical cannabis-specific CDS tool.

“We are dedicated to finding new ways to create value for our physician network. We continue to receive multiple requests from physicians who ask about how best to incorporate medical cannabis into their clinics. This agreement with CB2 will provide us a robust, validated tool to give our physicians and healthcare practitioners a safe and secure way to qualify, educate and where appropriate, prescribe medical cannabis to their patients in a compliant manner.”

Dr. Essam Hamza, CEO of Premier Health Group Inc

stock_price_marijuana

Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to June 1, 2019. As of 3/26/2019 Midam has been compensated an additional $100,000 by Premier Health Group for additional coverage without further extended coverage duration. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.Please click here for full disclaimer.

Continue Reading
Click to comment

Biotechnology

3 Small-Cap Biotech Stocks To Watch In Coming Weeks

Joe Samuel

Published

on

stock market today

Biotech has been one of the hottest sectors for investors for as long as it has existed and the reasons are self-evident. It is a sector that uses cutting edge technology and comes up with treatments for a wide range of diseases.

Moreover, the fact that biotech companies often improve on existing treatments, makes them a far more attractive target for a range of investors. Here is a look at three biotech stocks to watch during the last few weeks of the quarter.

PharmaCyte Biotech (PMCB)

There has been no lack of attention on biotech penny stocks this year.  At the beginning of August, one small biotech stock broke to highs of over $10 from a starting price below $2 a share after releasing news. PharmaCyte Biotech (PMCB) focuses on ways to effectively deliver treatments to patients with diseases ranging from cancer to diabetes. 

The company’s proprietary cellulose-based live-cell encapsulation technology known as “Cell-in-a-Box®is the platform that the company uses to develop its therapy delivery methods.  For most of the quarter, shares of PMCB stock have traded between $0.033 and $0.04 with volume recently surging.

On September 19, PharmaCyte saw more than 6 million shares trade; well above its daily average. Most of the attention surrounding the company has been on two things. First, its progress with Cell-In-A-Box and the application for Pancreatic cancer has continued to progress. The company brought on Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) now that he is at Weill Cornell Medical Center.

What To Watch For

This week PharmaCyte (PMCB) will host a call designed to update all shareholders and the investment community simultaneously of material developments. The call will cover PharmaCyte’s preparations for submission of its Investigational New Drug application (IND) to the U.S. FDA to treat locally advanced, inoperable pancreatic cancer. It will also cover developments related to PharmaCyte’s product pipeline. PharmaCyte has been working on these and will discuss things not yet reported in a press release.

Catalyst Pharmaceuticals (CPRX)

The first one to watch is Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). It is a small-cap stock engaged in developing medicines for rare diseases. Catalyst managed to get an approval for one of its products from the FDA earlier this year.

Since the approval of the Lambert-Eaton myasthenic syndrome (LEMS treating medicine Firdapse, Catalyst stock went on a massive rally from January to April. The approval of a rival drug halted the rally. Only after a civil suit from Catalyst did the stock stabilize somewhat.

Last week, Catalyst stock received a fresh boost after the company announced that it was going to make a secondary offering. However, the company decided to pull the offering the very next day and that affected the stock price once again.

What To Watch For

Analysts believe that pulling the secondary offering was the right long term decisions and this stock could be heading for another rally soon.

Eyepoint Pharmaceuticals (EYPT)

The biotech stock that could prove to be a major winner in the biotech sector this month is that of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT). There are two factors at play. The company revenues are going to rise significantly in the coming years due to the commercial launch of two medicines.

The first one is Yutiq, which is meant for the treatment of chronic non-infectious uveitis and the other one is Dexycu, which is meant for postoperative ocular inflammation.

What To Watch For

The company is currently trading at only double that of its future revenue and that is a very attractive multiple. EYPT stock has caught the attention of analysts on Wall Street. Guggenheim has set a 12-month target price of $4, which reflects 116% gains during the period.

stock market news today
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 9/12/2019. We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Featured

Stock Price Newsletter – September 20, 2019

Joe Samuel

Published

on

defense stocks to watch

Microsoft (MSFT) Stock Price Jumps On Increased Dividend and Buyback Announcement

On Wednesday Microsoft Corporation (NASDAQ: MSFT) shares gained 1% in extended trading after the company announced that it was raising its quarterly dividend by $0.05. But there’s more to this story than meets the eye.

Click To Read More


Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key

There’s no denying that biotechnology is one of the hottest markets in the world. Right now a multi-billion-dollar segment is ready for a shakeup and one biotech stock could hold the secret to doing just that!

Read More


Top 4 Penny Stocks To Watch Right Now

Penny stocks are some of the most active and volatile types of stocks in the stock market today. But what everyone knows about these is that they can break out in a big way. That’s why so many continue to look for the best penny stocks to buy.

See For Yourself

Continue Reading

Featured

Microsoft (MSFT) Stock Price Jumps On Increased Dividend and Buyback Announcement

Joe Samuel

Published

on

On Wednesday Microsoft Corporation (NASDAQ: MSFT) shares gained 1% in extended trading after the company announced that it was raising its quarterly dividend by $0.05.

Share Repurchase Program

The company has also authorized a $40 billion stock buyback. Under the leadership of CEO Satya Nadella, the company has been buying back its shares. In the fiscal year ended June 30, Microsoft bought back it’s a stock worth around $19.54 billion. The year before stock buybacks were around $10.72 billion. In the last five years under the tenure of Nadella, the company has seen it’s stock almost quadruple and exceed a trillion-dollar market cap.

The company has aggressively been repurchasing its stock and at the current rate, they are likely to use all the $40 billion in the latest repurchase program within two years. The new share repurchase program does not have an expiration period but the company could choose to terminate it any time.

Growing Dividends

The company is increasing its dividends by 5 cents barely a year after increased them. The board of directors approved a $0.51 quarterly dividend which reflects an 11% increase over the quarter before. This translates to $2.04 annually. Microsoft has been paying dividends to stockholders since 2003 and it has been pumping up its quarterly dividend each year.

Microsoft has indicated that it will pay shareholders of record on November 21 a dividend of $0.51 on December 12. The 11% increase is an improvement from last year’s dividend increase of 9.5%. The increase is slightly more than the company’s average dividend growth percentage of around 10.4%.

The share repurchase program and dividend increase are a no brainer for Microsoft. In 2019 the company brought around $38.3 billion in free cash flow of which $13.8 billion was given to shareholders in the form of dividends. The company returned around $33 billion to shareholders this is inclusive of the cash spent on stock repurchases.

Considering how trivial the company’s dividends are relative to its free cash flow, it appears like Microsoft will keep increasing its dividends each year.

A Clear Focus On Groundbreaking Technology

Global spending on security solutions is projected to reach $7.4 billion in 2019 and increase to over $11.3 billion by 2025 with a CAGR of 8.2%.  The urban Security explosives and Weapons Detection market is slated to grow to nearly $7.5 billion by 2025 and is forecast to see consistent growth for the next several years [2].

What does this mean? Well, for investors it could signal big opportunities but with so many large companies targeting surveillance systems and weapon detection devices as a “go-to,” is there anything that could truly disrupt this market?

In short, yes

Liberty Defense (SCAN.V) (LDDFF) Is Positioning To Change The Face Of Threat Detection For Good

The truth of the matter is that mass shootings now happen more than once a day in the US and as we’ve come to find, there’s no real way to stop these attacks after an attacker enters a space. This is where the real opportunity is: stopping an attack before someone even enters a vulnerable space.

Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) plans to do that using HEXWAVE, a next-generation high-tech security scanning system that will use advanced, low-power radar, 3D-imaging, and Artificial Intelligence (AI) to screen people at public gatherings such as sports games, unobtrusively.

Liberty Defense (SCAN.V) (LDDFF) Is Positioning To Change The Face Of Threat Detection For Good

The truth of the matter is that mass shootings now happen more than once a day in the US and as we’ve come to find, there’s no real way to stop these attacks after an attacker enters a space. This is where the real opportunity is: stopping an attack before someone even enters a vulnerable space.

Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) plans to do that using HEXWAVE, a next-generation high-tech security scanning system that will use advanced, low-power radar, 3D-imaging, and Artificial Intelligence (AI) to screen people at public gatherings such as sports games, unobtrusively.

Liberty Defense WSJ

The advanced attack prevention system can detect if someone is armed before they enter a building using radar energy and Artificial Intelligence (AI) to detect weapons and explosives in real-time. You may be thinking that the processes and screening technology that you see in airports can achieve the same thing in our communities.  

Urban Threat Detection

But we’re talking about urban detection; where high people traffic flow and attempts to provide airport-like screening processes can be extremely disruptive to business activity because of security entry delays. 

As important to providing a higher rate of threat screening is that there also needs to be a way to detect other potential mass attack weapons including explosives, pyrotechnics and other non-metallic threats.

Utilizing a new disruptive technology under an exclusive global license from MIT (Massachusetts Institute of Technology), Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) is developing HEXWAVE.

Liberty Defense WSJ

The advanced attack prevention system can detect if someone is armed before they enter a building using radar energy and Artificial Intelligence (AI) to detect weapons and explosives in real-time. You may be thinking that the processes and screening technology that you see in airports can achieve the same thing in our communities.  But we’re talking about urban detection; where high people traffic flow and attempts to provide airport-like screening processes can be extremely disruptive to business activity because of security entry delays. 

As important to providing a higher rate of threat screening is that there also needs to be a way to detect other potential mass attack weapons including explosives, pyrotechnics and other non-metallic threats.

Utilizing a new disruptive technology under an exclusive global license from MIT (Massachusetts Institute of Technology), Liberty Defense (TSX: SCAN.V) (OTC: LDDFF) is developing HEXWAVE.

Click Here To Learn More About Liberty Defense and its HEXWAVE

defense stocks weapons detection
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Liberty Defense Holdings Inc. Midam was hired for a period from 06/1/2019 – 9/30/2019 to publicly disseminate information about Liberty Defense Holdings Inc. including on the Website and other media including Facebook and Twitter. We were paid $250,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Liberty Defense Holdings Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. For previous compensation see our FULL DISCLAIMER HERE

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com